Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025GlobeNewsWire • 09/25/25
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/24/25
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?Zacks Investment Research • 09/23/25
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS ObservedGlobeNewsWire • 09/21/25
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 PresentationBusiness Wire • 09/17/25
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meetingGlobeNewsWire • 09/16/25
Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?Zacks Investment Research • 09/04/25
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in SeptemberGlobeNewsWire • 09/02/25
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo NordiskInvestors Business Daily • 08/28/25
Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive QuartersThe Motley Fool • 08/20/25
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The UpsideSeeking Alpha • 07/31/25
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call TranscriptSeeking Alpha • 07/30/25
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/30/25
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 EarningsInvestors Business Daily • 07/30/25